ERBB2 and cancer: To investigate whether FASN might contribute to innate cancer cell resistance to cytotoxic T cells, we examined how loss of FASN impacted the response of PD-L1-overexpressing JIMT-1 cells, a model of highly aggressive trastuzumab-resistant and anti-PD-L1 poorly responder HER2 + /basal-like breast cancer [82–86], to CATs.